This site is intended for healthcare professionals

PDS Biotech completes enrollment of lead-in safety cohort in VERSATILE-002 phase II combination trial

Read time: 1 mins
Last updated:10th Sep 2021
Published:10th Sep 2021
PDS Biotechnology Corporation announced that it has completed the enrollment of the lead-in safety cohort of its VERSATILE-002 Phase II study evaluating the efficacy and safety of the combination of PDS 0101, a clinical stage immunotherapy to treat cancers caused by infection with the human papillomavirus (HPV), and Keytruda (pembrolizumab), a checkpoint inhibitor (CPI)
Condition: Head & Neck Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest